Wealthspire Advisors (Maryland)’s Sarepta Therapeutics SRPT Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,557	Closed	-$250K	–	473
2020 Q1	$250K	Buy	2,557 +32	+1%	+$3.66K	0.02%	341
2019 Q4	$326K	Buy	+2,525	New	+$255K	0.02%	356
2019 Q2	–	Sell	-607	Closed	-$72K	–	1803
2019 Q1	$72K	Buy	607 +600	+8,571%	+$77.1K	0.01%	759
2018 Q4	$1K	Sell	7 -32	-82%	-$4K	﹤0.01%	2324
2018 Q3	$6K	Sell	39 -43	-52%	-$5.88K	﹤0.01%	1749
2018 Q2	$11K	Buy	+82	New	+$7.73K	﹤0.01%	1511

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s SRPT Position: Q2 2020 in Review

Wealthspire Advisors (Maryland) sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 2,557 shares — an estimated $250K sold.

Wealthspire Advisors (Maryland) first reported a position in SRPT in Q2 2018 and held it in 6 quarters. The position peaked at $326K in Q4 2019. 408 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

Wealthspire Advisors (Maryland) reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 2,557 Sarepta Therapeutics shares in Q2 2020, an estimated $250K.
Wealthspire Advisors (Maryland) first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 6 quarters.
Wealthspire Advisors (Maryland)'s Sarepta Therapeutics position peaked at $326K in Q4 2019.
408 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2020, filed 14 Aug 2020.